While injectable GLP-1 medications have seen high demand, the complexity of administration and strict fasting requirements for existing oral options have posed challenges for long-term adherence
Pioglitazone, a diabetes medication, may benefit selected patients with biopsy-proven NASH, but is also specialist-led and off-label , with potential risks including weight gain, fluid retention, heart failure, and increased fracture risk
Tirzepatide has not yet been shown to reduce the risk of heart attack or stroke, but studies on this are underway
How semaglutide could interact: dehydration warnings and common GI reactions provide a plausible route for symptom worsening in susceptible patients, without establishing drug-specific mucosal toxicity
Starting and stopping is something that I certainly see in my clinic, Dr